US2012220755A1PendingUtilityA1
Organic cation transporter polypeptides

Assignee: NEZU JUN-ICHIPriority: Sep 8, 1997Filed: Mar 14, 2011Published: Aug 30, 2012
Est. expirySep 8, 2017(expired)· nominal 20-yr term from priority
Inventors:Jun-Ichi Nezu Asuka Oku Akira Tsuji
C07K 14/47
PatentIndex Score
Cited by
References
Claims
Abstract

Novel genes significantly homologous to organic cation transporters OCT1 and OCT2 have been successfully isolated by screening a fetal gene library by random sequencing. Proteins encoded by these genes function as transporters of various organic cations.
Claims

exact text as granted — not AI-modified
1 . A substantially pure polypeptide comprising an amino acid sequence at least 70% identical to SEQ ID NO.: 3, wherein the polypeptide is a transporter of an organic cation. 
     
     
         2 . The polypeptide of  claim 1 , wherein the amino acid sequence is at least 80% identical to SEQ ID NO: 3. 
     
     
         3 . The polypeptide of  claim 1 , wherein the amino acid sequence is at least 90% identical to SEQ ID NO: 3. 
     
     
         4 . The polypeptide of  claim 1 , wherein the amino acid sequence is at least 95% identical to SEQ ID NO: 3. 
     
     
         5 . A substantially pure polypeptide comprising the sequence of SEQ ID NO: 3. 
     
     
         6 . A substantially pure polypeptide comprising the amino acid sequence of SEQ ID NO: 3, with up to 30 conservative amino acid substitutions, wherein the polypeptide is a transporter of an organic cation. 
     
     
         7 . A substantially pure polypeptide encoded by a nucleic acid that hybridizes to a probe the sequence of which consists of SEQ ID NO.:4, under conditions of: hybridization at 68° C., followed by washing in 2×SSC/0.1% SDS for 20 minutes at room temperature and twice in 0.1×SSC/0.1% SDS for 20 minutes at 50° C., wherein the polypeptide is a transporter of an organic cation. 
     
     
         8 .- 27 . (canceled) 
     
     
         28 . A substantially pure polypeptide comprising an amino acid sequence that is at least 70% identical to SEQ ID NO:3, wherein the polypeptide is a transporter of an organic cation, and wherein the polypeptide comprises the sequence Xaa1-Xaa2-Xaa3-Xaa4-Xaa5-Xaa6-Xaa7-Gly-Arg-Xaa8-Xaa9-Xaa10-Xaa11-Xaa12 (SEQ ID NO:33), wherein
 Xaa1 is Leu, Ile, Val, Met, Ser, Thr, Ala, or Gly;   Xaa2 is Leu, Ile, Val, Met, Phe, Ser, Ala, or Gly;   Xaa3 is any amino acid;   Xaa4 is Leu, Ile, Val, Met, Ser, Ala;   Xaa5 is Asp or Glu;   Xaa6 is any amino acid;   Xaa7 is Leu, Ile, Val, Met, Phe, Tyr, Trp, or Ala;   Xaa8 is Arg or Lys;   Xaa9 is any amino acid;   Xaa10 is any amino acid;   Xaa11 is any amino acid; and   Xaa12 is Gly, Ser, Thr, or Ala.   
     
     
         29 . A substantially pure polypeptide consisting of the sequence of SEQ ID NO:3. 
     
     
         30 . The polypeptide of  claim 28 , wherein the amino acid sequence is at least 76% identical to SEQ ID NO:3. 
     
     
         31 . The polypeptide of  claim 28 , wherein the amino acid sequence is at least 80% identical to SEQ ID NO:3. 
     
     
         32 . The polypeptide of  claim 28 , wherein the amino acid sequence is at least 90% identical to SEQ ID NO:3. 
     
     
         33 . The polypeptide of  claim 28 , wherein the amino acid sequence is at least 95% identical to SEQ ID NO:3. 
     
     
         34 . A substantially pure polypeptide comprising an amino acid sequence at least 76% identical to SEQ ID NO:3, wherein the polypeptide is a transporter of an organic cation, and wherein the polypeptide has 11 to 12 transmembrane domains. 
     
     
         35 . The polypeptide of  claim 34 , wherein the amino acid sequence is at least 80% identical to SEQ ID NO:3. 
     
     
         36 . The polypeptide of  claim 34 , wherein the amino acid sequence is at least 90% identical to SEQ ID NO:3. 
     
     
         37 . The polypeptide of  claim 34 , wherein the amino acid sequence is at least 95% identical to SEQ ID NO:3. 
     
     
         38 . A substantially pure polypeptide comprising an amino acid sequence at least 76% identical to SEQ ID NO: 3, wherein the polypeptide is a transporter of an organic cation, and wherein the polypeptide has a GTP/ATP binding domain ([Ala, Gly]-Xaa(4)-Gly-Lys-[Ser, Thr]). 
     
     
         39 . The polypeptide of  claim 38 , wherein the amino acid sequence is at least 80% identical to SEQ ID NO:3. 
     
     
         40 . The polypeptide of  claim 38 , wherein the amino acid sequence is at least 90% identical to SEQ ID NO:3. 
     
     
         41 . The polypeptide of  claim 38 , wherein the amino acid sequence is at least 95% identical to SEQ ID NO:3. 
     
     
         42 . A substantially pure polypeptide comprising an amino acid sequence at least 76% identical to SEQ ID NO:3, wherein the polypeptide is a transporter of an organic cation, and wherein the polypeptide has (a) 11 to 12 transmembrane domains, (b) a GTP/ATP binding domain ([Ala, Gly]-Xaa(4)-Gly-Lys-[Ser, Thr], and (c) the sequence: Xaa1-Xaa2-Xaa3-Xaa4-Xaa5-Xaa6-Xaa7-Gly-Arg-Xaa8-Xaa9-Xaa10-Xaa11-Xaa12 (SEQ ID NO:33), wherein
 Xaa is any amino acid;   Xaa1 is Leu, Ile, Val, Met, Ser, Thr, Ala, or Gly;   Xaa2 is Leu, Ile, Val, Met, Phe, Ser, Ala, or Gly;   Xaa3 is any amino acid;   Xaa4 is Leu, Ile, Val, Met, Ser, Ala;   Xaa5 is Asp or Glu;   Xaa6 is any amino acid;   Xaa7 is Leu, Ile, Val, Met, Phe, Tyr, Trp, or Ala;   Xaa8 is Arg or Lys;   Xaa9 is any amino acid;   Xaa10 is any amino acid;   Xaa11 is any amino acid; and   Xaa12 is Gly, Ser, Thr, or Ala.   
     
     
         43 . The polypeptide of  claim 42 , wherein the amino acid sequence is at least 80% identical to SEQ ID NO:3. 
     
     
         44 . The polypeptide of  claim 42 , wherein the amino acid sequence is at least 90% identical to SEQ ID NO:3. 
     
     
         45 . The polypeptide of  claim 42 , wherein the amino acid sequence is at least 95% identical to SEQ ID NO:3. 
     
     
         46 . A substantially pure human transport polypeptide comprising an amino acid sequence at least 76% identical to SEQ ID NO:3, wherein the polypeptide is a transporter of an organic cation, and wherein the polypeptide has (a) 11 to 12 transmembrane domains, (b) a GTP/ATP binding domain ([Ala, Gly]-Xaa(4)-Gly-Lys-[Ser, Thr], and (c) the sequence: Xaa1-Xaa2-Xaa3-Xaa4-Xaa5-Xaa6-Xaa7-Gly-Arg-Xaa8-Xaa9-Xaa10-Xaa11-Xaa12 (SEQ ID NO:33),
 wherein Xaa is any amino acid;   Xaa1 is Leu, Ile, Val, Met, Ser, Thr, Ala, or Gly;   Xaa2 is Leu, Ile, Val, Met, Phe, Ser, Ala, or Gly;   Xaa3 is any amino acid;   Xaa4 is Leu, Ile, Val, Met, Ser, or Ala;   Xaa5 is Asp or Glu;   Xaa6 is any amino acid;   Xaa7 is Leu, Ile, Val, Met, Phe, Tyr, Trp, or Ala;   Xaa8 is Arg or Lys;   Xaa9 is any amino acid;   Xaa10 is any amino acid;   Xaa11 is any amino acid; and   Xaa12 is Gly, Ser, Thr, or Ala.   
     
     
         47 . The polypeptide of  claim 46 , wherein the amino acid sequence is at least 80% identical to SEQ ID NO:3. 
     
     
         48 . The polypeptide of  claim 46 , wherein the amino acid sequence is at least 90% identical to SEQ ID NO:3. 
     
     
         49 . The polypeptide of  claim 46 , wherein the amino acid sequence is at least 95% identical to SEQ ID NO:3.
Cited by (0)

No later patents cite this yet.
References (0)

No backward citations on record.